Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RUFINAMIDE vs SACITUZUMAB GOVITECAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RUFINAMIDE vs SACITUZUMAB GOVITECAN: Safety Overview

Metric RUFINAMIDE SACITUZUMAB GOVITECAN
Total FAERS Reports 871 1,261
Deaths Reported 27 353
Death Rate 3.1% 28.0%
Hospitalizations 229 530
Average Patient Age 16.9 yrs 57.3 yrs
% Female Patients 50.2% 89.0%
FDA Approval Date Apr 15, 2025 N/A
Manufacturer Aurobindo Pharma Limited Gilead Sciences, Inc.
Route ORAL INTRAVENOUS
Marketing Status Discontinued N/A